JP2023522990A - Ｓａｒｓの治療のための化合物 - Google Patents

Ｓａｒｓの治療のための化合物 Download PDF

Info

Publication number
JP2023522990A
JP2023522990A JP2022564281A JP2022564281A JP2023522990A JP 2023522990 A JP2023522990 A JP 2023522990A JP 2022564281 A JP2022564281 A JP 2022564281A JP 2022564281 A JP2022564281 A JP 2022564281A JP 2023522990 A JP2023522990 A JP 2023522990A
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522990A5 (https=
JPWO2021216195A5 (https=
Inventor
アルン ケイ． ゴーシュ
裕明 満屋
モニカ ヤーダブ
アンドリュー メセカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2023522990A publication Critical patent/JP2023522990A/ja
Publication of JP2023522990A5 publication Critical patent/JP2023522990A5/ja
Publication of JPWO2021216195A5 publication Critical patent/JPWO2021216195A5/ja
Priority to JP2025104709A priority Critical patent/JP2025134881A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
JP2022564281A 2020-04-23 2021-02-23 Ｓａｒｓの治療のための化合物 Pending JP2023522990A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104709A JP2025134881A (ja) 2020-04-23 2025-06-20 Ｓａｒｓの治療のための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063014501P 2020-04-23 2020-04-23
US63/014,501 2020-04-23
US202063120079P 2020-12-01 2020-12-01
US63/120,079 2020-12-01
PCT/US2021/019285 WO2021216195A1 (en) 2020-04-23 2021-02-23 Compounds for the treatment of sars

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104709A Division JP2025134881A (ja) 2020-04-23 2025-06-20 Ｓａｒｓの治療のための化合物

Publications (3)

Publication Number Publication Date
JP2023522990A true JP2023522990A (ja) 2023-06-01
JP2023522990A5 JP2023522990A5 (https=) 2024-02-14
JPWO2021216195A5 JPWO2021216195A5 (https=) 2024-02-14

Family

ID=78269813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022564281A Pending JP2023522990A (ja) 2020-04-23 2021-02-23 Ｓａｒｓの治療のための化合物
JP2025104709A Pending JP2025134881A (ja) 2020-04-23 2025-06-20 Ｓａｒｓの治療のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104709A Pending JP2025134881A (ja) 2020-04-23 2025-06-20 Ｓａｒｓの治療のための化合物

Country Status (10)

Country Link
US (1) US20230159516A1 (https=)
EP (1) EP4139280A4 (https=)
JP (2) JP2023522990A (https=)
KR (1) KR20230005240A (https=)
CN (1) CN115667209A (https=)
AU (1) AU2021259145A1 (https=)
BR (1) BR112022021381A2 (https=)
CA (1) CA3176370A1 (https=)
MX (1) MX2022013081A (https=)
WO (1) WO2021216195A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
JP2024102382A (ja) * 2021-05-18 2024-07-31 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有する化合物
JP2024522990A (ja) * 2021-06-02 2024-06-25 エイシア セラピューティクス， インコーポレイテッド 抗ウイルス薬としてのプロテアーゼ阻害剤
WO2022266363A1 (en) * 2021-06-16 2022-12-22 The Scripps Research Institute Protease inhibitors for the treatment of coronavirus infections
CN114456211B (zh) * 2021-09-03 2024-03-26 中国药科大学 一种拟肽类化合物及其制备方法和应用
CN115806570B (zh) * 2021-11-15 2023-09-12 南京知和医药科技有限公司 一种拟肽衍生物及其药物组合物和用途
US20240228535A1 (en) * 2022-11-22 2024-07-11 Merck Sharp & Dohme Llc Protease inhibitors for treating or preventing coronavirus infection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515591A (ja) * 1999-12-03 2003-05-07 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗ピコルナウイルス化合物及び組成物、その医薬的使用及びその合成のための物質
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20050143319A1 (en) * 2003-12-31 2005-06-30 Taigen Biotechnology Protease inhibitors
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
CN103130710A (zh) * 2011-11-29 2013-06-05 南开大学 抗肠病毒71(ev71)己内酰胺醛类化合物及其制备方法和用途
US20140243341A1 (en) * 2011-09-27 2014-08-28 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
WO2017114509A1 (zh) * 2015-12-31 2017-07-06 中国科学院上海药物研究所 醛基类化合物及其制法和用途
WO2020030143A1 (zh) * 2018-08-09 2020-02-13 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US20110269834A1 (en) * 2008-08-21 2011-11-03 The Board Of Trustees Of The University Of Illinois Compounds and methods for treating respiratory diseases
CN107043334B (zh) * 2011-06-08 2020-06-16 日东电工株式会社 用于定向药物输送和增强siRNA活性的化合物
GB2595975B (en) * 2020-06-09 2022-12-07 Pardes Biosciences Inc Inhibitors of cysteine proteases and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515591A (ja) * 1999-12-03 2003-05-07 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗ピコルナウイルス化合物及び組成物、その医薬的使用及びその合成のための物質
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20050143319A1 (en) * 2003-12-31 2005-06-30 Taigen Biotechnology Protease inhibitors
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
US20140243341A1 (en) * 2011-09-27 2014-08-28 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
CN103130710A (zh) * 2011-11-29 2013-06-05 南开大学 抗肠病毒71(ev71)己内酰胺醛类化合物及其制备方法和用途
WO2017114509A1 (zh) * 2015-12-31 2017-07-06 中国科学院上海药物研究所 醛基类化合物及其制法和用途
WO2020030143A1 (zh) * 2018-08-09 2020-02-13 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 65, JPN6024051988, 2013, pages 436 - 447, ISSN: 0005645784 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 68, JPN6024051989, 2013, pages 372 - 384, ISSN: 0005645783 *
J. MED. CHEM., vol. 58, JPN6024051987, 2015, pages 9414 - 9420, ISSN: 0005645785 *

Also Published As

Publication number Publication date
JP2025134881A (ja) 2025-09-17
KR20230005240A (ko) 2023-01-09
EP4139280A4 (en) 2024-08-07
MX2022013081A (es) 2022-11-10
US20230159516A1 (en) 2023-05-25
BR112022021381A2 (pt) 2022-12-06
CN115667209A (zh) 2023-01-31
AU2021259145A1 (en) 2022-11-10
EP4139280A1 (en) 2023-03-01
CA3176370A1 (en) 2021-10-28
WO2021216195A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP2023522990A (ja) Ｓａｒｓの治療のための化合物
WO2022251615A1 (en) Compounds for the treatment of sars
US12466792B2 (en) Compounds for the treatment of SARS
JP2023525359A (ja) Ｓａｒｓの治療のための化合物
WO2022119858A1 (en) Compounds for the treatment of sars
US20220411401A1 (en) Compounds for the treatment of sars
TW201827056A (zh) 用於預防及／或治療多囊性腎臟病之藥物
US20240408062A1 (en) Compounds for the treatment of sars
JP7176767B2 (ja) 新規なアモジアキン類似体およびその使用方法
US20240409510A1 (en) Compounds for the treatment of sars
JP7711088B2 (ja) Ｓａｒｓの治療のための化合物
WO2022119854A1 (en) Compounds for the treatment of sars
US20240101541A1 (en) Compounds for the treatment of sars

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250722